Open AccessSurveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection
Author(s) -
Kristy Kummerow Broman,
Deepti Bettampadi,
Jaileene PérezMorales,
James Sun,
Д. А. Кириченко,
Michael J. Carr,
Zeynep Eroglu,
Ahmad A. Tarhini,
Nikhil I. Khushalani,
Matthew B. Schabath,
Amod A. Sarnaik,
Ver K. Sondak,
Jonathan S. Zager
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-021-10570-5
Subject(s) - medicine , adjuvant therapy , dissection (medical) , sentinel lymph node , radiology , lymph node , surgical oncology , nodal , ultrasound , melanoma , adjuvant , surgery , retrospective cohort study , cancer , chemotherapy , breast cancer , cancer research
Adjuvant therapy trials required completion lymph node dissection (CLND) for sentinel lymph node (SLN)-positive melanoma prior to systemic treatment, but nodal surveillance without CLND is now common. For patients receiving adjuvant therapy without CLND, patterns of recurrence are unknown and the value of regional nodal ultrasound alongside cross-sectional imaging is not well-defined.